We are live on ! Find out more
SCM

Soleus Capital Management Portfolio holdings

AUM $2.47B
1-Year Est. Return 115.63%
This Fund
S&P 500
This Quarter Est. Return
+22.99%
1 Year Est. Return
+115.63%
3 Year Est. Return
+435.52%
5 Year Est. Return
+604.31%
10 Year Est. Return
–
AUM
$758M
AUM Growth
+$569M
Cap. Flow
+$474M
Cap. Flow %
62.53%
Top 10 Hldgs %
80.56%
Holding
85
New
22
Increased
12
Reduced
26
Closed
20

Top Buys

Rank Stock Value
1
BCAB icon
BioAtla
BCAB
+$106M
2
DMRA
Damora Therapeutics, Inc. Ordinary Shares
DMRA
+$22.5M
3
NVTA
Invitae Corporation
NVTA
+$11.7M
4
EXEL icon
Exelixis
EXEL
+$8.18M
5
CCCC icon
C4 Therapeutics
CCCC
+$7.79M

Top Sells

Rank Stock Value
1
OSUR icon
OraSure Technologies
OSUR
+$7.61M
2
QDEL icon
QuidelOrtho
QDEL
+$6.75M
3
IMMU
Immunomedics Inc
IMMU
+$6.49M
4
SRPT icon
Sarepta Therapeutics
SRPT
+$6.48M
5
INBX
Inhibrx, Inc. Common Stock
INBX
+$5.13M

Sector Composition

Rank Sector Weight
1 Healthcare 43.51%
2 Consumer Staples 0.62%
3 Real Estate 0.32%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BIIB icon
51
Biogen
BIIB
$30.7B
$955K 0.13%
3,899
-7,657
-66% -$1.98M
HZNP
52
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$926K 0.12%
12,655
-39,572
-76% -$2.94M
RVNC
53
DELISTED
Revance Therapeutics, Inc.
RVNC
$882K 0.12%
31,136
-10,481
-25% -$271K
MDNA
54
DELISTED
Medicenna Therapeutics Corp. Common Shares
MDNA
$874K 0.12%
186,799
-62,061
-25% -$250K
KYMR icon
55
Kymera Therapeutics
KYMR
$8.94B
$813K 0.11%
13,116
-2,189
-14% -$107K
BHVN
56
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$657K 0.09%
+7,661
New +$649K
KRYS icon
57
Krystal Biotech
KRYS
$9.66B
$625K 0.08%
+10,423
New +$521K
FATE icon
58
Fate Therapeutics
FATE
$326M
$621K 0.08%
6,830
-2,882
-30% -$179K
AXGN icon
59
Axogen
AXGN
$2.5B
$605K 0.08%
33,813
-101,298
-75% -$1.49M
ALPN
60
DELISTED
Alpine Immune Sciences Inc
ALPN
$517K 0.07%
+41,064
New +$403K
TARA icon
61
Protara Therapeutics
TARA
$232M
$390K 0.05%
16,093
-83,907
-84% -$1.81M
OAC.WS
62
DELISTED
Oaktree Acquisition Corp. Warrants, each whole warrant exercisable for one Class A Ordinary Share at
OAC.WS
$358K 0.05%
+91,793
New +$196K
STAA icon
63
STAAR Surgical
STAA
$1.21B
$261K 0.03%
3,300
-12,046
-78% -$881K
AFMD
64
DELISTED
Affimed
AFMD
– –
-6,849
Closed -$232K
BPMC
65
DELISTED
Blueprint Medicines
BPMC
– –
-20,454
Closed -$1.9M
COGT icon
66
Cogent Biosciences
COGT
$7.24B
– –
-11,975
Closed -$112K
CSTL icon
67
Castle Biosciences
CSTL
$979M
– –
-6,269
Closed -$323K
DVAX
68
DELISTED
Dynavax Technologies
DVAX
– –
-167,798
Closed -$725K
ENTA icon
69
Enanta Pharmaceuticals
ENTA
$400M
– –
-11,500
Closed -$526K
IONS icon
70
Ionis Pharmaceuticals
IONS
$9.4B
– –
-19,648
Closed -$932K
IRTC icon
71
iRhythm Holdings
IRTC
$4.2B
– –
-1,187
Closed -$283K
LRMR icon
72
Larimar Therapeutics
LRMR
$432M
– –
-76,184
Closed -$1.16M
OSUR icon
73
OraSure Technologies
OSUR
$279M
– –
-625,109
Closed -$7.61M
PCRX icon
74
Pacira BioSciences
PCRX
$997M
– –
-10,200
Closed -$613K
PODD icon
75
Insulet
PODD
$9.79B
– –
-3,632
Closed -$859K
1 2
3
4

Similar funds

TW
Trajan Wealth Scottsdale, Arizona $2.48B AUM 17.44% 1-Year Est. Return
M
Mirova Paris, France $2.46B AUM 11.42% 1-Year Est. Return
SG
Sourcerock Group Denver, Colorado $2.48B AUM 72.25% 1-Year Est. Return
FFA
First Foundation Advisors Irvine, California $2.48B AUM 18.56% 1-Year Est. Return
GWM
Greenwich Wealth Management Greenwich, Connecticut $2.45B AUM 39.53% 1-Year Est. Return
Q
QVR San Francisco, California $2.49B AUM 48.58% 1-Year Est. Return
SIM
Stratos Investment Management Beachwood, Ohio $2.49B AUM 17.24% 1-Year Est. Return
QT
Quantbot Technologies New York $2.44B AUM 17.13% 1-Year Est. Return

Soleus Capital Management's Q4 2020 Portfolio in Review

As of Q4 2020, Soleus Capital Management held 85 positions worth $758M, up 302% from $189M the previous quarter. Its ten largest holdings account for 81% of the portfolio.

Soleus Capital Management deployed $474M of net new capital in Q4 2020, opening 22 new positions and adding to 12 existing holdings. Its largest new stake was BioAtla: 63,587 shares worth $108M.

By sector, the portfolio is most concentrated in Healthcare at 44% of assets, down from 94% a quarter earlier, followed by Consumer Staples and Real Estate.

On the sell side, the largest reduction was Inhibrx, Inc. Common Stock, an estimated $5.13M trimmed.

  • Soleus Capital Management's largest Q4 2020 buy was BioAtla: 63,587 shares worth $108M.
  • Soleus Capital Management added most to LYRA THERAPEUTICS INC in Q4 2020, an estimated $3.89M increase.
  • Soleus Capital Management's biggest Q4 2020 reduction was Inhibrx, Inc. Common Stock, cutting an estimated $5.13M.
  • Soleus Capital Management fully exited OraSure Technologies in Q4 2020, selling an estimated $7.61M.
  • Soleus Capital Management's ten largest holdings make up 81% of its $758M portfolio in Q4 2020.
  • Soleus Capital Management opened 22 new positions and closed 20 in Q4 2020.
  • Soleus Capital Management's portfolio value rose 302% quarter-over-quarter to $758M.

Based on Soleus Capital Management's 13F filing for Q4 2020, filed 16 Feb 2021.